CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Semnur Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Semnur Pharmaceuticals Inc
960 San Antonio Road
Phone: (650) 516-4310p:650 516-4310 PALO ALTO, CA  94303  United States Ticker: SMNRSMNR
Business Summary
Semnur Pharmaceuticals, Inc. is a clinical-late stage specialty pharmaceutical company focused on the development and commercialization of non-opioid pain therapies. The Company's lead program, SP-102, is non-opioid gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica. It is developing SP-102 to address problems associated with corticosteroid products that are used in practice but not approved for epidural injection or the treatment of sciatica. SP-102 is a Phase III sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a pre-filled glass syringe for delivery via an epidural injection. SP-102 allows for use of potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is formulated without the use of preservatives and packaged in a pre-filled syringe.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes---

Industries
SIC Code Description
6726 Unit investment trusts, face-amount certificate offices
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director LeiHuang 53
Chief Financial Officer YouSun 37
Independent Director HuifengChang 59 4/1/2022 4/1/2022
Independent Director JimMao 57 4/1/2022 4/1/2022
Independent Director Kevin D.Vassily 57 4/1/2022 4/1/2022

Business Names
Business Name
DECA
DECAU
Denali Merger Sub Inc.
DNQAF
SMNR

General Information
Outstanding Shares: 229,740,978 (As of 12/3/2025)
Shareholders: 11
Stock Exchange: OTC
Fax Number: (302) 636-5454


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 28, 2026